NCT04269031 - A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 13, 2020

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions

Healthy Volunteers

Interventions

DRUG

AZD2373 subcutaneous injection

Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).

DRUG

Placebo

Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.

Trial Locations (1)

Research Site, Brooklyn